The FDA granted a new indication for blinatumomab (Blincyto, Amgen) for the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
OCTOBER 14, 2016
OCTOBER 14, 2016
The FDA granted a new indication for blinatumomab (Blincyto, Amgen) for the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-) relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).